Respiratory Diseases Research Center, The Second Affiliated Hospital of Medical College, Xi'an Jiaotong University, Xi'an, Shaanxi, 710004, PR China.
Life Sci. 2011 Oct 24;89(17-18):644-9. doi: 10.1016/j.lfs.2011.07.023. Epub 2011 Aug 9.
To examine whether calcineurin/NFAT signaling pathway leads to proliferation of pulmonary artery smooth muscle cells (PASMCs) by regulating cell cycle proteins and whether the phosphodiesterase-5 (PDE5) inhibitor sildenafil affects calcineurin/NFAT-induced cell proliferation.
A [(3)H]thymidine incorporation assay was used to examine DNA synthesis (cell proliferation); cyclin A and NFATc2 expressions were determined by Western blot. Cyclin-dependent kinase 2 (CDK2) activity was measured with an in vitro kinase activity assay, and calcineurin and NFAT activity were evaluated using a calcineurin assay kit and a luciferase activity assay, respectively. A chemical inhibitor or siRNA transfection was used to inhibit calcineurin/NFAT signaling pathway.
Serotonin dose-dependently stimulated cyclin A expression in PASMCs. This effect was accompanied by dose-dependent increases in CDK2 activity and the rate of DNA synthesis. At the same time, PASMCs treated with serotonin showed dose-dependent activation of calcineurin/NFAT signaling pathway. Inhibition of calcineurin activity by cyclosporine A or loss of NFATc2 protein by siRNA transfection abolished serotonin-induced cyclin A expression and consequent CDK2 activation and DNA synthesis. We further found that pretreatment of cells with sildenafil suppressed serotonin-triggered activation of calcineurin/NFATc2 signaling pathway and resultant cyclin A expression, CDK2 activation and cell proliferation, while the presence of DT-3 [a specific protein kinase G (PKG) peptide inhibitor] reversed the effects of sildenafil on PASMCs.
Our study suggests that enhanced PKG activity suppresses calcineurin/NFATc2 cascade-mediated cyclin A expression, CDK2 activation and PASMC proliferation to contribute to the overall effects of sildenafil in the treatment of pulmonary hypertension.
通过调节细胞周期蛋白来研究钙调神经磷酸酶/NFAT 信号通路是否导致肺动脉平滑肌细胞(PASMC)增殖,并研究磷酸二酯酶-5(PDE5)抑制剂西地那非是否影响钙调神经磷酸酶/NFAT 诱导的细胞增殖。
采用[3H]胸腺嘧啶核苷掺入法检测 DNA 合成(细胞增殖);用 Western blot 检测细胞周期蛋白 A 和 NFATc2 的表达。用体外激酶活性测定法测定细胞周期蛋白依赖性激酶 2(CDK2)的活性,用钙调神经磷酸酶测定试剂盒和荧光素酶活性测定法分别评估钙调神经磷酸酶和 NFAT 的活性。用化学抑制剂或 siRNA 转染抑制钙调神经磷酸酶/NFAT 信号通路。
血清素可剂量依赖性地刺激 PASMC 中细胞周期蛋白 A 的表达。这种作用伴随着 CDK2 活性和 DNA 合成率的剂量依赖性增加。同时,用血清素处理的 PASMC 表现出钙调神经磷酸酶/NFAT 信号通路的剂量依赖性激活。用环孢菌素 A 抑制钙调神经磷酸酶活性或用 siRNA 转染敲除 NFATc2 蛋白,可消除血清素诱导的细胞周期蛋白 A 表达及随后的 CDK2 激活和 DNA 合成。我们进一步发现,细胞预先用西地那非处理可抑制血清素触发的钙调神经磷酸酶/NFATc2 信号通路的激活及由此产生的细胞周期蛋白 A 表达、CDK2 激活和细胞增殖,而存在 DT-3(一种特异性蛋白激酶 G(PKG)肽抑制剂)则可逆转西地那非对 PASMC 的作用。
我们的研究表明,增强的 PKG 活性抑制钙调神经磷酸酶/NFATc2 级联介导的细胞周期蛋白 A 表达、CDK2 激活和 PASMC 增殖,从而有助于西地那非在治疗肺动脉高压中的整体作用。